Brensocatib Reduced Bronchiectasis Exacerbations, Improved Symptoms in Asian Patients
The phase 3 ASPEN trial revealed brensocatib 10 mg and 25 mg significantly reduced bronchiectasis exacerbations, prolonged time to first exacerbation, and improved quality-of-life scores.
